Quantum Computing Inc. Common
QUBT
$11.10
+11.78%
Quantum Computing Inc. (QUBT) is a technology company focused on developing and delivering integrated photonics and non-linear quantum optics machines for quantum computing, reservoir computing, remote sensing, imaging, and cybersecurity applications. It operates as a niche player in the emerging quantum computing hardware and software industry, aiming to produce systems that operate at room temperature and low power. The current investor narrative is intensely focused on the sector-wide rally and speculative boom driven by major government investment, new AI tools for quantum error correction, and the landmark IPO of competitor Quantinuum, which is forcing a critical test of whether QUBT can capitalize on rising tides or be cannibalized by better-funded rivals.…
QUBT
Quantum Computing Inc. Common
$11.10
Related headlines
Investment Opinion: Should I buy QUBT Today?
Rating & Thesis: Hold. QUBT is a purely speculative bet on long-term quantum computing adoption, unsuitable for most investors due to its extreme valuation risk, lack of current earnings, and high volatility; the absence of a clear analyst consensus underscores this uncertainty.
Supporting Evidence: The recommendation is anchored by several critical data points: the astronomical trailing PS ratio of 2,474.6x indicates extreme overvaluation relative to any rational benchmark. Revenue remains negligible at $198k with erratic quarterly trends, showing no consistent commercial traction. The company is deeply unprofitable with a net margin of -27.38% and burns $36.98 million annually in free cash flow. While the balance sheet is strong (current ratio 102.38), this only provides a runway for continued speculation, not fundamental value.
Risks & Conditions: The two biggest risks are catastrophic multiple compression from the current PS ratio and a failure to achieve projected revenue growth before cash runs low. This Hold rating would upgrade to a speculative Buy only if the company demonstrates a clear, material commercial contract that validates its technology and provides a credible path to the analyst's $1.48 billion revenue projection. It would downgrade to a Sell if quarterly revenue fails to show sequential growth, if cash burn accelerates, or if the stock breaks below its key technical support at $6.18. The stock is unequivocally overvalued based on all conventional metrics, with its price reflecting wildly optimistic future scenarios.
Sign up to view all
QUBT 12-Month Price Forecast
The AI assessment is bearish due to the profound disconnect between valuation and fundamentals. While the quantum computing sector offers long-term potential, QUBT's specific risk/reward is skewed negatively. The stock prices in a near-flawless commercialization story, but the current financials show a company in the earliest R&D stage with high cash burn. The stance would upgrade to neutral only upon evidence of sustainable, material revenue generation (e.g., consistent quarterly revenue >$1M) and a stabilization of the cash burn rate. Until then, the high probability of valuation compression and operational setbacks supports a cautious view.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Quantum Computing Inc. Common's 12-month outlook, with a consensus price target around $14.43 and implied upside of +30.0% versus the current price.
Average Target
$14.43
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$9 - $14
Analyst target range
Analyst coverage for QUBT is minimal, with only one analyst providing estimates, indicating limited institutional interest and higher volatility due to inefficient price discovery. The single analyst projects substantial future growth, with an estimated average EPS of $2.03 and average revenue of $1.48 billion, figures that represent a monumental leap from current operational levels and should be viewed as highly speculative. Without a consensus price target or recommendation distribution, it is impossible to calculate a clear implied upside or downside; the available data shows a pattern of institutional ratings, with firms like Rosenblatt and Ascendiant Capital maintaining 'Buy' ratings as recently as March 2026, while Cantor Fitzgerald has a 'Neutral' stance. The wide gap between the analyst's lofty financial projections and the company's current reality, coupled with the recent exit of a major institutional investor (Anson Funds), signals very high uncertainty and low conviction in the near-term path to monetization, making the stock a purely speculative bet on long-term quantum computing adoption.
Bulls vs Bears: QUBT Investment Factors
The evidence currently leans bearish due to the chasm between QUBT's astronomical valuation and its pre-commercial financial reality. The bull case rests entirely on speculative sector tailwinds and future potential, while the bear case is grounded in concrete, current operational deficiencies and valuation risk. The single most important tension in the investment debate is whether QUBT can achieve the analyst-projected leap to $1.48 billion in revenue before its cash runway expires or before competition from better-funded rivals renders its technology obsolete. The resolution of this commercialization timeline versus cash burn race will determine the investment outcome.
Bullish
- Sector Rally and Government Investment: The quantum computing sector is experiencing a major rally fueled by a $2 billion U.S. government investment and Nvidia's AI tools for error correction, creating a rising tide for all players. This macro tailwind provides a supportive environment for QUBT's speculative narrative, as evidenced by the stock's 36.03% surge over the last 3 months.
- Strong Balance Sheet with Minimal Debt: The company maintains a fortress-like liquidity position with a current ratio of 102.38 and a negligible debt-to-equity ratio of 0.001. This strong financial footing provides a multi-year runway to fund R&D without the immediate risk of insolvency, despite burning significant cash.
- Analyst Projections for Monumental Growth: The single covering analyst projects average future revenue of $1.48 billion, representing a massive leap from the current $198k quarterly run-rate. While speculative, this forecast underscores the transformative potential priced into the stock if commercialization succeeds.
- Recent Technical Recovery Off Lows: After a severe decline, the stock has moved 38% above its 52-week low of $6.18, suggesting a potential basing phase. The 3-month price surge of 36.03% dramatically outperformed the S&P 500, indicating renewed speculative interest.
Bearish
- Astronomical Valuation with No Earnings: The stock trades at a trailing Price-to-Sales ratio of 2,474.6x and an EV/Sales of 289.4x, reflecting extreme speculation against negligible revenue of $198k. This valuation leaves the stock highly vulnerable to catastrophic multiple compression if growth timelines slip.
- Pre-Commercial Revenue and Deep Losses: Revenue is minuscule and erratic, with Q4 2025 sales of only $198k and a net margin of -27.38%. The company is deeply unprofitable, burning $36.98 million in free cash flow (TTM), indicating commercialization is years away and dependent on continuous equity financing.
- Extreme Volatility and Institutional Skepticism: The stock's beta of 3.74 means it is 274% more volatile than the market, with a maximum drawdown of -74.37%. Major institutional investor Anson Funds recently exited its position entirely, signaling deep skepticism about near-term monetization prospects.
- Intense Competition from Better-Funded Rivals: The landmark IPO of competitor Quantinuum introduces a new, well-capitalized leader that could cannibalize smaller players like QUBT. With only 77 employees, QUBT faces a significant scale disadvantage against deep-pocketed rivals in a capital-intensive race.
QUBT Technical Analysis
The stock is in a volatile, long-term downtrend, evidenced by a 1-year price change of -43.29% and a 6-month change of -17.59%. Currently trading at $9.93, it sits near the lower end of its 52-week range, approximately 38% above its 52-week low of $6.18 and 62% below its 52-week high of $25.84, indicating the stock remains deeply depressed from its highs but has moved off its absolute lows, suggesting a potential basing or value-seeking phase after a severe decline. Recent momentum shows a sharp but volatile recovery, with a 3-month price surge of 36.03% dramatically outperforming the S&P 500's 12.0% gain, yet this is contradicted by a 1-month decline of -9.97%, indicating the rally may be losing steam or experiencing a pullback. This divergence highlights the stock's extreme volatility, which is further confirmed by its beta of 3.74, meaning it is approximately 274% more volatile than the broader market, a critical factor for risk management. Key technical levels are clearly defined, with immediate resistance near the 52-week high of $25.84 and support at the recent low of $6.18; a sustained breakout above the recent May highs near $12.70 would signal a stronger recovery trend, while a breakdown below the March low of $6.18 would likely trigger a new leg down. The stock's extreme beta and a maximum drawdown of -74.37% over the provided period underscore its speculative, high-risk nature, suitable only for investors with a high-risk tolerance and a long-term horizon.
Beta
3.74
3.74x market volatility
Max Drawdown
-74.4%
Largest decline past year
52-Week Range
$6-$26
Price range past year
Annual Return
-33.5%
Cumulative gain past year
| Period | QUBT Return | S&P 500 |
|---|---|---|
| 1m | +5.7% | +2.1% |
| 3m | +47.2% | +12.5% |
| 6m | +8.6% | +12.4% |
| 1y | -33.5% | +26.4% |
| ytd | +0.8% | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
QUBT Fundamental Analysis
Revenue remains minuscule and highly erratic, with the most recent quarterly revenue at only $198k, representing a modest year-over-year growth of 2.19%. The multi-quarter trend shows extreme volatility, from $39k in Q1 2025 to $384k in Q3 2025, back down to $198k in Q4 2025, indicating the company is in the earliest pre-commercialization stage with no consistent revenue trajectory. This underscores that the investment case is purely based on future potential, not current business performance. The company is deeply unprofitable, with a net income of -$1.56 million in Q4 2025 and a trailing twelve-month net margin of -27.38%. Gross margin was negative at -49.49% for the quarter, though it has swung wildly from -24.67% to +42.62% in prior quarters, reflecting the immaterial and inconsistent cost structure relative to tiny revenue. Operating expenses of $22.1 million in Q4 2025 vastly overshadow gross profit, indicating the business is burning significant cash on R&D and G&A to develop its technology, with profitability likely years away. The balance sheet shows a fortress-like liquidity position with a current ratio of 102.38 and minimal debt, evidenced by a debt-to-equity ratio of 0.001. However, cash flow is deeply negative, with operating cash flow of -$11.02 million and free cash flow of -$36.98 million on a TTM basis, indicating the company is entirely dependent on external financing (equity issuance) to fund its operations, as shown by $718.6 million in net cash from financing in Q4 2025. The return on equity is negative at -0.012, confirming the destruction of shareholder value under current operations.
Quarterly Revenue
$198000.0B
2025-12
Revenue YoY Growth
+2.19%
YoY Comparison
Gross Margin
-0.49%
Latest Quarter
Free Cash Flow
$-36984000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is QUBT Overvalued?
Given the company's consistent net losses, the primary valuation metric is the Price-to-Sales (PS) ratio, as earnings-based multiples are not meaningful. The trailing PS ratio is an astronomically high 2,474.6x, reflecting the market's extreme speculation on future growth against currently negligible sales of $198k. The forward-looking EV/Sales ratio is also elevated at 289.4x, though significantly lower than the trailing PS, suggesting analysts project a massive revenue ramp. A direct peer comparison is challenging due to the lack of industry average data in the provided valuation set, but such an extreme sales multiple indicates QUBT trades at a massive premium to any rational benchmark, justified only by the speculative potential of the quantum computing market. Historically, the stock's own valuation has been wildly volatile; its current PS ratio of 2,474.6x is down from a recent high of 8,417.6x at the end of Q4 2025 but remains near the upper end of its multi-year range, which has seen figures from zero (when revenue was nil) to over 44,000x. Trading near historical highs on a sales multiple basis signals the market is still pricing in extraordinarily optimistic future revenue growth, leaving the stock vulnerable to severe multiple compression if commercialization timelines slip or competition intensifies.
PE
-90.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -268x~310x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-69.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: QUBT faces severe financial risks stemming from its pre-revenue stage. The company is burning cash at an alarming rate, with TTM free cash flow of -$36.98 million and operating cash flow of -$11.02 million, entirely dependent on equity issuance (evidenced by $718.6 million in financing cash flow in Q4 2025) to fund operations. Revenue is negligible at $198k per quarter and highly volatile, swinging from $39k to $384k, indicating no predictable business model. Furthermore, profitability is non-existent, with a net margin of -27.38% and a negative return on equity of -0.012, confirming ongoing shareholder value destruction.
Market & Competitive Risks: The primary market risk is extreme valuation compression. Trading at a PS ratio of 2,474.6x, the stock is priced for perfection and would face a severe derating if revenue growth disappoints. Competitively, the recent Quantinuum IPO creates a well-funded rival that could dominate customer and capital markets attention. The stock's beta of 3.74 also makes it hypersensitive to broader market downturns and sector rotation away from speculative tech. Recent news highlights the sector rally as potentially driven by 'hype and FOMO,' masking unsustainable valuations.
Worst-Case Scenario: The worst-case scenario involves a failure to commercialize combined with a sector-wide sentiment shift. This could trigger a chain of events: a missed development milestone leads to analyst downgrades, the cash burn rate accelerates dilution through further equity raises, and Quantinuum captures early adopter contracts. Realistic downside could see the stock re-test its 52-week low of $6.18, representing a loss of approximately -38% from the current price of $9.93. Given the stock's history of a -74.37% drawdown, a drop of 50-60% is plausible in a full sector de-rating, potentially driving the price toward $4-$5.
FAQ
The key risks are, in order of severity: 1) Valuation Compression Risk: The extreme PS ratio of 2,474.6x could collapse if revenue growth disappoints, leading to massive share price declines. 2) Commercialization Failure: The company may never successfully monetize its technology, as evidenced by erratic quarterly revenue below $400k. 3) Financial Risk: The company burns $36.98M annually in free cash flow and is entirely dependent on dilutive equity financing to survive. 4) Competitive Risk: The emergence of well-funded rivals like the recently IPO'd Quantinuum could marginalize QUBT in the race for market share.
The 12-month forecast is highly uncertain and bifurcated into three scenarios. The base case (50% probability) sees the stock trading between $7 and $12, as it remains volatile but range-bound without fundamental progress. The bear case (30% probability) could see a drop to $4-$6 if commercialization fails and valuation compresses. The bull case (20% probability), driven by sector euphoria and a major partnership, could push the stock toward $20-$26. The most likely outcome is the base case, where the stock's extreme volatility continues but fails to break meaningfully higher due to the lack of tangible commercial traction.
QUBT is severely overvalued by any conventional metric. Its trailing Price-to-Sales ratio of 2,474.6x and EV/Sales of 289.4x are stratospheric, indicating the market is pricing in a near-perfect execution of a multi-billion dollar revenue future that is currently non-existent. Compared to its own history, the PS ratio remains near the upper end of its volatile range. This valuation implies the market expects the company to grow revenue by several thousand percent to justify the current price, making it highly vulnerable to a sharp correction if those expectations are tempered.
QUBT is not a good stock to buy for the vast majority of investors. It is a purely speculative bet with extreme risks, including an astronomical valuation (PS ratio of 2,474.6x), negligible revenue ($198k), and heavy cash burn (-$36.98M TTM FCF). It could only be considered by investors with a very high risk tolerance who are willing to accept the potential for total loss for a small chance of outsized returns if the company's technology is successfully commercialized years from now. The recent exit of a major institutional investor (Anson Funds) further underscores the low conviction in the near-term thesis.
QUBT is unsuitable for short-term investment due to its extreme volatility (beta of 3.74) and lack of near-term catalysts tied to earnings. It is theoretically a long-term investment, but only of the highest-risk, venture-capital variety. Given its pre-revenue status and multi-year path to potential profitability, any investment should have a minimum horizon of 5-7 years to allow for the technology cycle to play out. However, the high risk of dilution and business failure means it is not suitable for traditional long-term 'buy-and-hold' portfolios seeking stability or income, as it pays no dividend and exhibits destructive shareholder value metrics like a negative ROE.